n (%)
|
169 (76.8)
|
44 (20)
|
7 (3.2)
| |
Sex [n (%)]
| | | |
0.049
|
Male
|
103 (60.9)
|
23 (52.3)
|
7 (100)
| |
Female
|
66 (39.1)
|
21 (47.7)
|
0 (0)
| |
Age [years, [median (IR)]
|
43 (15)
|
51.5 (15)
|
45 (14)
|
0.027
|
Duration of HIV infection [years, [median (IR)]
|
8 (6)
|
8 (5.8)
|
8 (6)
|
0.782
|
cART [years, [median (IR)]
|
6 (7)
|
6 (5.8)
|
8 (6)
|
0.408
|
Clinical lipodystrophy [n (%)]
| | | |
0.082
|
Without CL
|
76 (45)
|
27 (61.4)
|
2 (28.6)
| |
With CL
|
93 (55)
|
17 (38.6)
|
5 (71.4)
| |
Body Composition [n (%)]
| | | |
0.004
|
No lipodystrophy
|
26 (15.8)
|
4 (9.8)
|
1 (14.3)
| |
Isolated central fat accumulation
|
46 (27.9)
|
22 (53.7)
|
1 (14.3)
| |
Lipoatrophy
|
52 (31.5)
|
6 (14.6)
|
0 (0)
| |
Mixed form of lipodystrophy
|
41 (24.8)
|
9 (22)
|
5 (71.4)
| |
BMI [(kg/m2), [median (IR)]
|
24.4 (5.8)
|
26.1 (5.5)
|
26 (3.4)
|
0.052
|
Waist circumference [cm, [median (IR)]
|
88 (16.5)
|
95 (13.5)
|
95 (15)
|
0.005
|
CD4 cell count [cells/mm3, [median (IR)]
|
486 (344)
|
525 (298)
|
605 (382)
|
0.643
|
HIV RNA (<50) [n (%)]
|
151 (100)
|
35 (100)
|
6 (100)
| |
Hepatitis C co-infection [n (%)]
|
56 (33.5)
|
6 (14.3)
|
2 (28.6)
|
0.034
|
CDC clinical categories [n (%)]
| | | |
0.398
|
A
|
89 (52.7)
|
27 (61.4)
|
3 (42.9)
| |
B
|
3 (1.8)
|
2 (4.5)
|
0 (0)
| |
C
|
77 (45.6)
|
15 (34.1)
|
4 (57.1)
| |
ART [n (%)]
| | | | |
IP
|
96 (56.8)
|
23 (52.3)
|
4 (57.1)
|
0.885
|
NNRTI
|
79 (46.7)
|
20 (45.5)
|
3 (42.9)
|
0.999
|
NRTI
|
163 (96.4)
|
41 (93.2)
|
6 (85.7)
|
0.157
|
HOMA-IR index [median (IR)]
|
1.5 (1.3)
|
3.2 (2.6)
|
9.3 (6,8)
|
< 0.001
|
QUICKI index [median (IR)]
|
0.4 (0.1)
|
0.3 (0.04)
|
0.3 (0.04)
|
< 0.001
|
Total cholesterol [mg/dL, median (IR)]
|
220 (66)
|
240.5 (86)
|
234 (79)
|
0.061
|
LDL- cholesterol [mg/dL, median (IR)]
|
127 (67)
|
149 (62)
|
146 (74)
|
0.136
|
HDL- cholesterol [mg/dL, median (IR)]
|
47 (18)
|
49 (22)
|
41 (22)
|
0.651
|
Triglycerides [mg/dL, median (IR)]
|
189.5 (197.8)
|
214.5 (207.8)
|
184 (88)
|
0.975
|
Statin use [n (%)]
|
35 (20.7)
|
8 (18.2)
|
3 (42.9)
|
0.312
|
Fibrate use [n (%)]
|
50 (29.6)
|
15 (34.1)
|
0 (0)
|
0.200
|